Standout Papers

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma 2005 2026 2012 2019 5.1k
  1. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma (2005)
    Monika E. Hegi, Annie‐Claire Diserens et al. New England Journal of Medicine
  2. CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cells Show Differential Growth Characteristics and Molecular Profiles (2007)
    Dagmar Beier, Peter Hau et al. Cancer Research

Immediate Impact

3 by Nobel laureates 19 from Science/Nature 176 standout
Sub-graph 1 of 13

Citing Papers

Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial
2024 Standout
Glioblastoma and Other Primary Brain Malignancies in Adults
2023 Standout
76 intermediate papers

Works of Peter Hau being referenced

EORTC Study 26041–22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma—Results of a phase I trial
2007
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
2005 Standout
and 15 more

Author Peers

Author Last Decade Papers Cites
Peter Hau 6746 4991 3162 187 11.6k
Annick Desjardins 6152 3169 2115 247 9.7k
Johannes A. Hainfellner 7285 5958 3057 296 14.5k
W.K. Alfred Yung 6307 7966 3154 175 14.7k
Howard Colman 5868 5534 3671 149 11.3k
Andrew E. Sloan 5925 4187 2591 220 13.6k
Daniel P. Cahill 4070 4201 2437 173 9.5k
Christel Herold‐Mende 5453 6169 3577 308 14.1k
Erik P. Sulman 3534 4943 2937 219 10.0k
David Capper 7594 5127 3331 227 13.0k
Olivier Chinot 7295 3036 2337 294 11.4k

All Works

Loading papers...

Rankless by CCL
2026